check categori
strong improv oper profil view time invest align
could much better particularli investor look healthcar franchis
rel shield medicar risk stock still
last year high result wed amc check box everi key metric
robust organ invisalign case volum growth exceed guidanc stabl
invisalign price key overhang better-than-expect gross
margin oper leverag sg expens materi ebit/ep upsid
rel expect total revenu mln beat street mln view
primarili volum growth believ investor also favor view
sequenti improv world-wide averag sell price asp vs
gross margin came compani guidanc even
exclud benefit one-tim item oper margin
exclud one-tim impair charg close invisalign store per smile direct
club arbitr outcom well guidanc strong
oper margin driven part effici manufactur higher
stronger volum ep vs street view street
estim includ expect incom mln settlement payment
straumann worth per share push
new ep guidanc substanti current street view
rais pt ep beyond pathway margin expans
current underutil china fabric facil ramp-up phase
also captur leverag increas market spend commenc
told rais ep ep
compani make strong oper gain absorb
higher corp/leg cost neg impact margin reiter ow rate
increas pt base pe multipl higher
ep look invisalign color confer may
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight compani market leader
clear align still earli stage
adopt clear align north american
market expect drive
upsid case see greater adopt clear
align better current project
believ would warrant multipl expans
given strong leverag greater ep growth
downsid case see continu asp declin
multipl compress growth compani fall
favor continu invest spend mute ep
growth would lead lower multipl
project
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
align post revenu mln compar street expect mln
compani guidanc mln case ship compar street
expect guidanc sequenti basi ww improv
improv estim na declin
gross margin came compani guidanc
quarterli gross margin benefit freight refund rebat
approxim given compani saw signific oper leverag
align product move compani undertaken improv
effici oper margin came slightli street within
compani guidanc howev oper margin depress
due impair charg relat sdc arbitr agreement
compani actual oper margin exclud particular item well
guid rang compani tax rate came compani guidanc
altogeth ep came vs street
compani guidanc continu see strong invisalign volum growth
growth y/i collect revenu expect mln well
street current mln view margin expect slight tick
freight rebat benefit expect repeat compani
also factor straumann settlement guidanc view add bp
compani oper margin compani guid oper
margin includ bp benefit settlement off-set bp relat
compani corp/leg cost suggest oper margin would
rang exclud settlement corp/leg cost line compani
also book ep gain divest sdc stake altogeth
compani expect ep well current street view
regard compani sdc stake management indic stake sold earli april
expect minor interest expens associ invest
move forward addit management expect volum sdc
compani move emea headquart netherland switzerland
expect occur middl year complet earli note
compani may abl drive lower tax rate move
note compani also bake straumann itero agreement current
could provid addit upsid straumann earli juli sign distribut
agreement pay mln nevertheless confid either situat
abl continu sell scanner robust rate
shipmentsmiddl rangemiddl sequentiallyinternationalup sequentiallyaspsflat rangemiddl mlninvisalign revenuesmiddl rangemiddl rangescannersmiddl rangemiddl rangeup sequentiallygross marginsimprov cours yearimprov cours lt lt sg mlnop marginimprov cours yearimprov cours op margin op margin rangestraumann contribut rangefi rangecorp/leg cost remov legal feesincl legal feestax incl mln excess tax incl mln excess tax mlnadjust mlnequiti loss mil/qtrnoteshir gp rep americas/emeahir gp rep americas/emeaect sdc volument expens org structur expens org structurestraumann gain ep stronger ep stronger sdc op profit op profit rangecorp structur re-org cost barclay align technolog
align year guidanc tablerevenu growthprovid analyst daygross analyst dayoper expens revsprovid analyst dayoper analyst revsprovid analyst daybuyback milprovid analyst day barclay align technolog
 annual revenu model align modelactualactualactualactualactualprojectedprojectedprojectedcas ship geographi american orthodontist exclud american gp dentist exclud america total exclud case ship exclud changenorth american orthodontist exclud american gp dentist exclud america total exclud case ship exclud mixnorth american orthodontist exclud american gp dentist exclud america total exclud case ship exclud sell price asp north american asp exclud asp provid exclud asp barclay changenorth american asp exclud asp provid exclud asp barclay align sale mil north america invisalign na north america includ changenorth america invisalign barclay
 annual incom statement addback check settlement expens rate interest check ep fulli dilut share growth expens barclay
 annual revenu model align modelactualactualactualprojectedprojectedprojectedcas ship geographi american orthodontist exclud american gp dentist exclud america total exclud case ship exclud changenorth american orthodontist exclud american gp dentist exclud america total exclud case ship exclud mixnorth american orthodontist exclud american gp dentist exclud america total exclud case ship exclud sell price asp north american asp exclud asp provid exclud asp barclay changenorth american asp exclud asp provid exclud asp barclay align sale mil north america invisalign na north america includ changenorth america invisalign barclay
 annual incom statement addback check settlement expens rate interest check ep fulli dilut share growth expens per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
